Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cardiovascular Disease Screening

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 27, 2016 by National Institutes of Health Clinical Center (CC)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ) Identifier:
First received: June 7, 2007
Last updated: April 20, 2017
Last verified: September 27, 2016

This study will evaluate volunteers 18 years of age and older to see if they qualify for one of NHLBI s research studies. Tests include the following:

  • General medical evaluation, which may include blood tests, chest x-ray, electrocardiogram (ECG) and echocardiogram (heart ultrasound).
  • Other tests as appropriate, such as magnetic resonance imaging (MRI), cardiac computed tomography (CT scan of the heart), nuclear stress test and echocardiography stress test.
  • X-ray contrast studies of the heart and blood vessels. (These may be excluded in patients with kidney risk factors.)

Congenital Heart Disease
Myocardial Ischemia
Myocardial Infarction
Acquired Heart Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Suburban/NHLBI Cardiovascular Disease Screening Protocol

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 99999999
Study Start Date: June 1, 2007
Detailed Description:

This is a screening protocol. This protocol allows two functions: 1) the protocol allows physicians in the Suburban/NHLBI Cardiovascular Imaging program to evaluate patients referred to the program with clinically indicated studies and research studies. 2) It is also designed to determine if patients may be suitable candidates for one of our NHLBI research protocols.

Patients greater than or equal to 18 years of age referred for possible cardiovascular disease will be enrolled in the protocol for a period of one year. At one year, patients will either be: 1) transferred to one of our specific research MRI or CT protocols, 2) removed from the screening protocol and made inactive, or 3) re-enrolled on the screening protocol with the patient s consent.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

No one will be excluded from this study based on race, gender, or ethnicity.

A. General Inclusion Criteria:

  • Age greater than or equal to 18
  • Capable of giving informed consent.

B. General Exclusion Criteria (for all arms):

  • Pregnant women (uncertain patients will have urine or blood testing).
  • Decompensated heart failure (unable to lie flat in bed).

Test Specific Exclusion Criteria:

A. CT Exclusion Criteria (excludes contrast enhanced CT scan only):

  • Allergy to iodinated contrast agent excludes contrast enhanced CT research studies.
  • Multiple myeloma.
  • Patients with severe kidney disease (eGFR less than 30 mL/min/1.73 m(2).

B. Beta Antagonist Exclusions (excluded the use of beta blocker only):

  • Asthma or severe chronic lung disease/emphysema with regular use of inhaler.
  • Decompensated heart failure.

C. MRI Exclusion Criteria (excludes MRI scan only):

  • Cardiac pacemaker or implantable defibrillator.
  • Cerebral aneurysm clip.
  • Neural stimulator (e.g. TENS-Unit).
  • Any type of ear implant.
  • Metal in eye (e.g. from machining).
  • Any implanted device (e.g. insulin pump, drug infusion device).

D. Exclusions from MRI contrast agents:

  • Lactating women unless they are willing to discard breast milk for 24 hours.
  • Severe kidney disease (less than 30 mL/min/1.73 m(2).

E. Vasodilator Exclusions (excludes some vasodilator stress testing):

  • Asthma or chronic obstructive pulmonary disease (emphysema) actively treated with bronchodilators or leukotriene receptor antagonists (albuterol, seravent, atrovent, montelukast singulair, zafirlukast Accolate. These conditions only exclude adenosine and dipyridamole.
  • Second degree (Type II) and third degree atrioventricular heart block.

F. Exclusions from Dobutamine stress MRI only:

  • Severe problems with heart rhythms.
  • Severe high blood pressure.

G. Exclusion criteria for atropine (given during dobutamine stress echocardiography when target heart rate not achievable with dobutamine alone).

  • Narrow angle glaucoma.
  • Known or suspected severe bladder outlet obstruction due to prostatic hypertrophy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00483951

Contact: Marsha Block, R.N. (301) 496-0211
Contact: Andrew E Arai, M.D. (301) 496-3658

United States, Maryland
Suburban Hospital Recruiting
Bethesda, Maryland, United States, 20814
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Andrew E Arai, M.D. National Heart, Lung, and Blood Institute (NHLBI)
  More Information

Additional Information:
Responsible Party: National Heart, Lung, and Blood Institute (NHLBI) Identifier: NCT00483951     History of Changes
Other Study ID Numbers: 070157
Study First Received: June 7, 2007
Last Updated: April 20, 2017

Keywords provided by National Institutes of Health Clinical Center (CC):
Myocardial Infarction
Myocardial Ischemia
Congenital Heart Disease
Valvular Heart Disease
Heart Disease
Cardiovascular Disease
Heart Valve Disease

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Heart Defects, Congenital
Coronary Artery Disease
Vascular Diseases
Arterial Occlusive Diseases
Cardiovascular Abnormalities
Coronary Disease
Myocardial Infarction
Myocardial Ischemia
Pathologic Processes
Congenital Abnormalities processed this record on April 28, 2017